Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3318004
Max Phase: Preclinical
Molecular Formula: C19H17ClFN5O2
Molecular Weight: 401.83
Molecule Type: Small molecule
Associated Items:
ID: ALA3318004
Max Phase: Preclinical
Molecular Formula: C19H17ClFN5O2
Molecular Weight: 401.83
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: O=C(O)[C@H]1[C@@H]2CC[C@@H](C2)[C@@H]1Nc1nc(-c2c[nH]c3ncc(Cl)cc23)ncc1F
Standard InChI: InChI=1S/C19H17ClFN5O2/c20-10-4-11-12(6-23-16(11)22-5-10)17-24-7-13(21)18(26-17)25-15-9-2-1-8(3-9)14(15)19(27)28/h4-9,14-15H,1-3H2,(H,22,23)(H,27,28)(H,24,25,26)/t8-,9+,14+,15+/m1/s1
Standard InChI Key: FOVHQWZLPKBKAD-IOWHJBRQSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 401.83 | Molecular Weight (Monoisotopic): 401.1055 | AlogP: 3.72 | #Rotatable Bonds: 4 |
Polar Surface Area: 103.79 | Molecular Species: ACID | HBA: 5 | HBD: 3 |
#RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 4.15 | CX Basic pKa: 2.58 | CX LogP: 3.26 | CX LogD: 0.34 |
Aromatic Rings: 3 | Heavy Atoms: 28 | QED Weighted: 0.62 | Np Likeness Score: -0.71 |
1. Clark MP, Ledeboer MW, Davies I, Byrn RA, Jones SM, Perola E, Tsai A, Jacobs M, Nti-Addae K, Bandarage UK, Boyd MJ, Bethiel RS, Court JJ, Deng H, Duffy JP, Dorsch WA, Farmer LJ, Gao H, Gu W, Jackson K, Jacobs DH, Kennedy JM, Ledford B, Liang J, Maltais F, Murcko M, Wang T, Wannamaker MW, Bennett HB, Leeman JR, McNeil C, Taylor WP, Memmott C, Jiang M, Rijnbrand R, Bral C, Germann U, Nezami A, Zhang Y, Salituro FG, Bennani YL, Charifson PS.. (2014) Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2., 57 (15): [PMID:25019388] [10.1021/jm5007275] |
Source(1):